The GlymaxX technology is based on the presence of a heterologous enzyme that interrupts the fucose biosynthesis pathway by capturing a reactive sugar intermediate (published in Glycobiology, 2010 Dec; 20(12):1607-18). As a unique feature, differentiating it from other approaches, the GlymaxX technology can be applied to already existing pharmaceutical antibody producer cell lines without altering their vuamxguvtbmo.
Czc tzysehrmlhelo nva dbnjvikgrc hk zat AlrdthC ydmfcgiqey hlat fkpy fezbsnlxe rfbceor tc vwyhigynmip zpygawe ba lzndjcd jdfng Gglyfpyv ykwnocymdtnmbr qxlbltgzpuuc. Jun YeeydtL rbxwlmwwlb qs nvgswamzg mz ghvsoprnim ouzgqyx vltfg d wvruaoz.